CN1132581C - Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitiors - Google Patents
Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitiors Download PDFInfo
- Publication number
- CN1132581C CN1132581C CN97115549A CN97115549A CN1132581C CN 1132581 C CN1132581 C CN 1132581C CN 97115549 A CN97115549 A CN 97115549A CN 97115549 A CN97115549 A CN 97115549A CN 1132581 C CN1132581 C CN 1132581C
- Authority
- CN
- China
- Prior art keywords
- mirtazapine
- ssri
- serotonin reuptake
- selective serotonin
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a pharmaceutical composition comprising mirtazapine, a selective serotonin reuptake inhibitor (SSRI) and pharmaceutically acceptable auxiliaries. In particular the SSRI is selected from fluoxetine, fluvoxamine, citalopram, cericlamine, femoxetine, sertraline, paroxetine, ifoxetine, cyanodothiepin and litoxetine. The composition which can be used to treat depressant patients has less side effects than treatment of the patients with mirtazapine or the SSRI alone.
Description
The present invention relates to contain the pharmaceutical composition of mirtazapine and selective serotonin reuptake inhibitor (SSRI), relate to the packing of the dosage unit that contains mirtazapine and a kind of selective serotonin reuptake inhibitor (SSRI), also relate to Therapeutic Method patients with depression.
Depression can act on the crowd of any age bracket as a kind of chronic disease.Though many effective antidepressant drugs are employed, the existing armarium of treatment usefulness is not competent usually, has about 1/3rd can not produce satisfied curative effect in whole treatment targets to making.In the polytype antidepressant that uses, selective serotonin reuptake inhibitor (SSRI) is wherein the most effective at present.SSRI has higher ratio to the inhibitory action of serotonin reuptake transporter with respect to the reuptake inhibition to norepinephrine.SSRI was employed as far back as the 1980s, and the SSRI zimelidine is the medicine that goes on the market the earliest.Other SSRI medicine also in succession listing or developing among, for example: fluoxetine, fluvoxamine, citalopram, cericlamine (cericlamine), femoxetine, ifoxetine, cyaniding dosulepin, desmethylimipramine, paroxetine, and Li Duxiting.Though SSRI occurs with respect to the better looks of classical antidepressants with it as the medicine of new breakthrough, the SSRI medicine still has been considered to many trouble parts because of its side effect, and this just makes, and the SSRI medicine is left out in the treatment of depression.In addition, some researcheres think, for the depressive patient subgroup SSRI medicine of melancholy than other antidepressant drug even more inferior.The pronounced side effects of SSRI medicine is headache, feel sick, appetite inhibiting and sexual dysfunction, and for example ahedonia and libido reduce.The side effect of this class sexual disorder easily with submit to and mutual interference mutually for a long time.
The application of finding now mirtazapine can prevent or reduce at least significantly and take the side effect that SSRI produces, and mirtazapine is a kind of up-to-date antidepressant and at US 4,062,848, in open.
Mirtazapine and SSRI have many surprising common traits.As SSRI, mirtazapine to muscarine can receptor, the norepinephrine reuptake carrier, and α-1-adrenoreceptor lower affinity is arranged, in addition, they can both improve the release of 5-hydroxy tryptamine.And opposite with SSRI, mirtazapine does not suppress neuronic 5-hydroxy tryptamine picked-up pump.The most important untoward reaction of mirtazapine in treatment is exactly drowsiness.An additional advantage of the present invention be exactly SSRI and mirtazapine when using simultaneously SSRI can reduce the side effect of mirtazapine.Thereby having the present invention relates to using of two kinds of dissimilar antidepressants, every kind of medicine has weakened the side effect of another kind of medicine each other.Find further that also two kinds of medicines can strengthen another kind of effect as antidepressants mutually.Therefore, SSRI can be used for more patient if use simultaneously with mirtazapine, keeps simultaneously or strengthens treatment.
Therefore one aspect of the present invention provides a kind of compositions, and it has comprised mirtazapine or its officinal salt and one or more SSRI or its officinal salt, preferably contains a kind of SSRI.Most preferred compositions comprises mirtazapine and a kind of SSRI.Above-mentioned these compositionss will be called compositions of the present invention after this.
No matter the chemical compound in the compositions is both can use simultaneously in identical or different pharmaceutical preparation, also use in succession discriminably.If use in succession, the delay administration of second (or additional) active component should not cause the loss of the useful effect benefit of active component combination.
Suitable salt comprises acid-addition salts, for example, hydrochloric acid, fumaric acid, maleic acid, citric acid or succinic acid, above-mentioned acid is only in order to explanation, but is not limited to this.
Mirtazapine, SSRI and their salt can contain one or more chiral centres, and possible stereoisomer has comprised diastereomer and enantiomer.The present invention has comprised above-mentioned stereoisomer in its scope, and single (R) of each chemical compound and salt thereof and (S) enantiomer, also has the mixture of these enantiomer with arbitrary proportion.In fact, the enantiomerism monomer can contain and be less than 5% another kind of enantiomer, preferably is less than 2%, especially preferably is less than 1%; Mixture of enantiomers can comprise the racemic modification of the basic mixed in equal amounts of two kinds of enantiomer.
The present invention also provides and has been used for the treatment of, in particular for treating into the present composition of prevention depression.
The invention still further relates to compositions of the present invention and be used to prepare the purposes of medicine with antidepressant activity and side effect minimum.The present invention also provides with mirtazapine preparation and one or more SSRI simultaneously or the purposes of the medicine of the treatment depression of sequential application, is ideally to prepare above-mentioned and mirtazapine simultaneously or the medicine used of interval with a kind of SSRI.
The invention still further relates to mirtazapine and a kind of SSRI be used to prepare have antidepressant activity and no headache, feel sick, the purposes of the medicine of side effect such as appetite inhibiting or sexual dysfunction.
The invention still further relates to a kind of treatment and suffer from the animal of depression, for example, comprise the mammiferous method of human patients, the method comprises the compositions of the present invention of using effective dose.
Method of the present invention is suitable for all SSRI.For example, mirtazapine or its officinal salt and fluoxetine, fluvoxamine, citalopram, cericlamine, femoxetine, spill in desmethylimipramine, Paro west, ifoxetine, cyaniding dosulepin and Li Duxiting, or their pharmaceutical salts.The compositions of one or more in mirtazapine and fluoxetine, fluvoxamine, citalopram, desmethylimipramine and the paroxetine is preferred.Preferred compositions also has the compositions of mirtazapine or its officinal salt and fluoxetine or its officinal salt.Most preferred compositions is the compositions of mirtazapine and fluoxetine.
Certainly, the amount that produces the compositions of required mirtazapine (or its officinal salt) of useful effect and SSRI (or its officinal salt) can change, and finally depends on medical personnel's judgement.The influence factor who need to consider comprises route of administration, dosage form, the weight of animals, age, integrated condition, and needs the sanatory character and the order of severity.
Usually, mirtazapine or its officinal salt have a scope to the suitable dosage that the people uses, be between the curer per kilogram of body weight every day 0.01-30mg, preferable range is 0.1-5mg per kilogram of body weight every day, and most preferred range is 0.3-1.0mg per kilogram of body weight every day.
Generally speaking, in 0.01-50mg per kilogram every day curer body weight, preferable range is 0.1-3mg per kilogram of body weight every day to people's suitable dose scope for SSRI or its officinal salt.For fluoxetine, the appropriate dosage scope is a 0.01-10mg per kilogram every day curer body weight, and preferable range is 0.1-1mg per kilogram of body weight every day.
Except as otherwise noted, the weight of all active components is all calculated by medicine itself.Required dosage can whole day with the interval that is fit in the gradation administration, can divide 2 times, 3 times, 4 times, 5 times or more sub-doses.These sub-doses can for example, comprise the 5-50mg mirtazapine with the unit dosage form administration, and preferred value is the 10mg mirtazapine.SSRI also can be with the unit dosage form administration, and dosage range is 10-100mg, and preferable range is 10-50mg.The dosage unit form of the conventional administration of fluorine Fu Tingming is 50-100mg, and the paroxetine dosage unit is 20mg, and desmethylimipramine is 50mg.Fluoxetine typical doses unit is 20mg.
Be referred to as the compositions component administration in a usual manner of active ingredient, be used for the treatment of animal, for example, mammal comprises the people.
When the active component of compositions might be with the form administration of crude drug, they are suitable made a kind of pharmaceutical preparation.Pharmaceutical preparation of the present invention has comprised active component (being the compositions of mirtazapine or its officinal salt and one or more SSRI or its officinal salt) and one or more pharmaceutically suitable carrier or excipient, and other therapeutic agent arbitrarily.Carrier must be suitable with preparation in other composition adapt, and harmless to curer.When the independent component of compositions was distinguished administration, they can make medicament respectively usually.
Suitable preparation comprises that those are suitable for the dosage form of oral administration, rectum, nose, part (comprising transdermal, oral film and Sublingual), intravaginal or parenteral (comprising subcutaneous, intramuscular, intravenous and percutaneous) administration.All preparations can prepare with known method on any pharmaceutics.For example, adopt people such as Gennaro, work " Remington ' s Pharmaceutical Science " (the 18th edition, Mack publishing company, nineteen ninety, referring to the 8th part: medication preparation and production thereof) described in method, this method comprises that wherein carrier is made up of one or more adjuvants with active component and carrier-bound step.These adjuvants have comprised the conventional ingredient in this field, for example, and filler, binding agent, diluent, disintegrating agent, lubricant, coloring agent, flavoring agent and lubricant.
Be applicable to that oral preparation can be made into separate unit, for example, pill, tablet or capsule wherein contain the active component of scheduled volume in each unit; As powder or granule; Solution or suspension.Active component also can be made into big ball or paste, or is wrapped in the liposome.
The preparation of rectally can be made into suppository or enema.
The suitable formulations of parenteral comprises aqueous and non-water aseptic injection.Preparation can be packed in unit dose or the multi-dose container, for example: and sealed vial or ampoule, and be stored under lyophilization (lyophilizing) condition, and only allow to add aseptic liquid phase carrier, for example water before use.
The preparation that is suitable for the nasal cavity suction comprises micropowder or mist agent, and they can provide by pressure aerosolizer, aerosol apparatus or the insufflator of metered dose.
The invention still further relates to the preparation technology of pharmaceutical preparation, it has comprised compositions and one or more pharmaceutically suitable carrier has been combined that wherein compositions is the compositions of mirtazapine (or its officinal salt) and one or more SSRI (or its officinal salt).
In a specific embodiment, the mixture of mirtazapine and one or more SSRI can be made into the pharmaceutical preparation of unit dosage form, for example, with tablet, form administrations such as ball or capsule.These dosage forms are well known in the art, as, the canonical reference book; People such as Gennaro work " Remington ' sPharmacentioal Science " (the 18th edition, Marck publishing company, nineteen ninety, emphasis is referring to the 8th part: medication preparation and production) described in, chemical compound can be pressed into solid dosage unit, as pill, tablet, or make capsule or suppository.If suitable pharmaceutical liquid also can be made injection with chemical compound, but its form solution, suspension, emulsion or spray, as nasal spray.
In order to prepare dosage form units, as tablet, can use conventional additives, for example filler, coloring agent, polymer adhesive etc.Usually the pharmaceutically acceptable interpolation material of any not interferon activity chemical compound function can use.The appropriate amount of active component is for example, to contain mirtazapine and the 5-100mgSSRI agent usually of 5-50mg in a slice.Particularly for example, contain 15mg mirtazapine and 20mg fluoxetine in a slice.When the active low SSRI of use itself, the amount of SSRI can be higher than 100mg.
Suitable carrier with the compositions administration comprises lactose, starch and cellulose derivative etc., or their mixture.Need suitable amount during use.
The pharmaceutical preparation of more generally writing out a prescription to the patient now is called " patient's medicated bag ", the medication of the whole course of treatment is housed, commonly blister pack in its single medicated bag.Patient's medicated bag has its superiority with respect to traditional prescription, and it is that the pharmacists can tell a patient's drug dose from big packing, and patient always can obtain the packing inserted in medicated bag, and this is impossible for the tradition prescription.Plug-in type packing be also advantageous in that it has improved the compliance of patient to doctor's advice.
Another embodiment relates to the packing that contains separate dosage units, and one or more dosage units contain mirtazapine or its officinal salt, and one or more dosage unit contains SSRI or its officinal salt.The dosage unit that contains mirtazapine (or its officinal salt) has the active component of appropriate amount, for example, and 5-50mg mirtazapine, and 10-30mgSSRI for example.Packing contains the tablet of q.s or capsule etc., is used for finishing the treatment of patient's predetermined treatment duration, for example 2 weeks, 1 month or 3 months.
Certainly, the patient also can use the separate dosage units treatment, and each separate dosage units only contains mirtazapine or a kind of SSRI.This separate dosage units is included within the packing described herein.
The present invention also comprises patient's medicated bag, wherein contains mirtazapine and SSRI, and has comprised that relevant active component is used in combination the information insert of explanation.
U.S. Pat 4,062,843 described methods are adopted in the preparation of mirtazapine, and it at this also as a reference.
SSRI can prepare with any known method.For example, fluoxetine and its pharmaceutically acceptable acid addition salts can adopt the method for preparing the structural similarity chemical compound well known in the art to prepare.Usually the used preparation method of chemical compound is described in U.S. Pat 4,314,081.The pharmaceutical composition that contains fluoxetine is described in US 4,194, in 009.U.S. Pat 4,314,081 and 4,194,009 content is at this as a reference.
The present invention further illustrates by following embodiment.
Embodiment 1
The sexual function of rats obstacle that fluoxetine causes:
Male rat is placed little cage respectively.Observe continuously.Handle rat with fluoxetine, their spontaneous abruptly erections, meansigma methods is 2.1 ± 0.3.This result is consistent with the work that Berendsen and Broekkamp are delivered in European J Pharmacol 135:279-287 (1987).
When handling rat simultaneously, remarkable and satisfactory to the reduction effect of erection phenomenon with fluoxetine and mirtazapine.0.1mg/kg the mirtazapine of dosage just is enough to this unusual effect of antagonism fluoxetine to sexual function.
Experimental result is the meansigma methods that derives from 11 rats.
Fluoxetine, 22mg/kgf, subcutaneous injection (SC): 2.1 ± 0.3 erect,
Fluoxetine, 22mg/kg, subcutaneous injection, ten mirtazapines,
0.1mg/kg erect in sc:0.2 ± 0.1
Fluoxetine, 22mg/kg, sc ten mirtazapine 0.22mg/kgf,
Erect in sc:0.4 ± 0.2.
Embodiment 2
The reduction of appetite inhibiting effect due to the fluoxetine:
Rat is put into the cage 30 minutes of the food that fills its happiness food.Their foods remove the food (meansigma methodss of 7 rats) of 14.5 ± 1.8g.Food is made up of the edible worm that lives.
The rat that crosses with 30mg/kg fluoxetine subcutaneous injection has only eaten 3 ± 0.4g, and appetite has reduced by 80%.In the contrast experiment, the mirtazapine of while subcutaneous injection 2mg/kg, appetite only reduces by 40%, and therefore, mirtazapine is significantly to the antagonism of the appetite inhibiting effect that fluoxetine causes, but has only partial action.
Claims (7)
1. a compositions comprises mirtazapine or its officinal salt and one or more selective serotonin reuptake inhibitors or its officinal salt.
2. according to the compositions described in the claim 1, wherein selective serotonin reuptake inhibitor is selected from: zimelidine, fluoxetine, fluvoxamine, citalopram, cericlamine, femoxetine, ifoxetine, cyaniding dosulepin, desmethylimipramine, paroxetine and Li Duxiting.
3. according to the compositions described in the claim 1, wherein contain mirtazapine and fluoxetine.
4. pharmaceutical preparation that comprises claim 1 compositions, compositions wherein combines with one or more pharmaceutically suitable carrier.
5. one or more selective serotonin reuptake inhibitors at preparation and mirtazapine simultaneously or administration in succession, be used for the treatment of the application in the medicine of depression.
6. mirtazapine at preparation and one or more selective serotonin reuptake inhibitors simultaneously or administration in succession, be used for the treatment of the application in the medicine of depression.
7. packing that contains separate dosage units, wherein one or more dosage units contain mirtazapine, and one or more other dosage unit contains selective serotonin reuptake inhibitor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96201703 | 1996-06-19 | ||
| EP96201703.4 | 1996-06-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1173330A CN1173330A (en) | 1998-02-18 |
| CN1132581C true CN1132581C (en) | 2003-12-31 |
Family
ID=8224094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97115549A Expired - Fee Related CN1132581C (en) | 1996-06-19 | 1997-06-19 | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitiors |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5977099A (en) |
| JP (2) | JP4925074B2 (en) |
| KR (1) | KR100481254B1 (en) |
| CN (1) | CN1132581C (en) |
| AR (1) | AR007609A1 (en) |
| AT (1) | ATE213159T1 (en) |
| AU (1) | AU727851B2 (en) |
| BR (1) | BR9703624A (en) |
| CA (1) | CA2208199C (en) |
| CZ (1) | CZ290691B6 (en) |
| DE (1) | DE69710390T2 (en) |
| DK (1) | DK0813873T3 (en) |
| ES (1) | ES2172744T3 (en) |
| HK (1) | HK1006081A1 (en) |
| HU (1) | HU225534B1 (en) |
| ID (1) | ID17051A (en) |
| IL (1) | IL121076A (en) |
| NO (1) | NO313177B1 (en) |
| NZ (1) | NZ328113A (en) |
| PL (1) | PL188520B1 (en) |
| PT (1) | PT813873E (en) |
| RU (1) | RU2181287C2 (en) |
| SG (1) | SG60073A1 (en) |
| TR (1) | TR199700522A2 (en) |
| ZA (1) | ZA975335B (en) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| AU737590B2 (en) * | 1997-11-14 | 2001-08-23 | N.V. Organon | Use of mirtazapine for treating sleep apneas |
| US6960577B2 (en) * | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
| US6727283B2 (en) | 1998-10-13 | 2004-04-27 | Pfizer Inc. | Sertraline oral concentrate |
| US6575147B2 (en) * | 1999-02-25 | 2003-06-10 | Go-Tec | Internal combustion system adapted for use of a dual fuel composition including acetylene |
| US6545149B2 (en) | 1999-04-19 | 2003-04-08 | Teva Pharmaceutical Industries Ltd. | Synthesis and crystallization of piperazine ring-containing compounds |
| EP1178805A4 (en) * | 1999-04-19 | 2004-11-24 | Teva Pharma | Novel synthesis and crystallization of piperazine ring-containing compounds |
| US6403657B1 (en) * | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
| US6759437B2 (en) * | 1999-10-04 | 2004-07-06 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
| MXPA02007095A (en) * | 2000-01-19 | 2003-04-14 | Akzo Nobel Nv | Drug combination for the treatment of depression and related disorders comprising mirtazapine. |
| AU2002212888A1 (en) * | 2000-11-01 | 2002-05-15 | Respiratorius Ab | Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4) |
| US6399310B1 (en) | 2001-02-12 | 2002-06-04 | Akzo Nobel N.V. | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
| US20030105082A1 (en) * | 2001-12-03 | 2003-06-05 | Murphy Greer Marechal | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
| JP2004532190A (en) * | 2001-02-12 | 2004-10-21 | アクゾ・ノベル・エヌ・ベー | Method for improving the treatment of major depression by genotyping the gene for apolipoprotein E4 |
| US20030181509A1 (en) * | 2002-03-21 | 2003-09-25 | Hinz Martin C. | Serotonin and catecholamine system segment optimization technology |
| US20090311795A1 (en) * | 2002-03-21 | 2009-12-17 | Hinz Martin C | Bilateral control of functions traditionally regulated by only serotonin or only dopamine |
| US20070293571A1 (en) * | 2006-06-08 | 2007-12-20 | Hinz Martin C | Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes |
| US20040229285A1 (en) * | 2003-02-21 | 2004-11-18 | Hinz Martin C. | Serotonin and catecholamine system segment optimization technology |
| AU2003295235B2 (en) | 2002-12-27 | 2008-06-19 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
| AR042806A1 (en) * | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | COMBINATION OF CARBOSTIRILE DERIVATIVES AND INHIBITORS OF SEROTONINE REABSORTION FOR THE TREATMENT OF ANIMO DISORDERS |
| TW200502222A (en) * | 2003-04-02 | 2005-01-16 | Novartis Ag | Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
| JP4343948B2 (en) | 2003-04-29 | 2009-10-14 | オレキシジェン・セラピューティクス・インコーポレーテッド | Composition for affecting weight loss |
| US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
| US7838029B1 (en) | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
| US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
| ES2426915T3 (en) | 2003-09-10 | 2013-10-25 | Brentwood Equities Ltd. | Diastereoisomers of 4-aryloxy-3-hydroxypiperidines |
| US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
| TW200538100A (en) * | 2004-04-21 | 2005-12-01 | Akzo Nobel Nv | Mirtazapine salts |
| US20060039867A1 (en) * | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders with setiptiline |
| EP1827450A4 (en) * | 2004-11-17 | 2009-04-22 | Cypress Bioscience Inc | Methods for reducing the side effects associated with mirtazapine treatment |
| WO2006053884A1 (en) * | 2004-11-19 | 2006-05-26 | N.V. Organon | Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression |
| ES2761812T3 (en) | 2005-11-22 | 2020-05-21 | Nalpropion Pharmaceuticals Inc | Composition and methods of increasing insulin sensitivity |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| JP2010509367A (en) | 2006-11-09 | 2010-03-25 | オレキシジェン・セラピューティクス・インコーポレーテッド | Laminated formulation |
| MX2009004871A (en) | 2006-11-09 | 2009-06-16 | Orexigen Therapeutics Inc | Methods for administering weight loss medications. |
| EP2167096A4 (en) * | 2007-06-13 | 2010-07-14 | Cypress Bioscience Inc | Improving the tolerability of mirtazapine and a second active by using them in combination |
| CN101332193B (en) * | 2007-06-29 | 2012-12-12 | 杭州民生药业有限公司 | Preparation method of fluvoxamine maleate medicine composition |
| WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| US8768578B2 (en) | 2009-06-09 | 2014-07-01 | Sumitomo Heavy Industries, Ltd. | Hybrid excavator and method of controlling hybrid excavator |
| US8785453B2 (en) * | 2009-11-13 | 2014-07-22 | Green Cross Corporation | Arylpiperazine-containing purine derivatives and uses thereof |
| CA2785822C (en) | 2010-01-11 | 2019-06-25 | Orexigen Therapeutics, Inc. | Methods of providing weight loss therapy in patients with major depression |
| CN102000334B (en) * | 2010-10-15 | 2012-02-22 | 北京大学 | Compound preparation for treating depression |
| RU2475235C2 (en) * | 2011-03-15 | 2013-02-20 | Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" | Pharmaceutical composition for prevention and treatment of depressions |
| AR085840A1 (en) * | 2011-04-05 | 2013-10-30 | Otsuka Pharma Co Ltd | MEDICINAL PRODUCT CONTAINING A COMPOUND THAT IS 7- [4- (4-BENZO [B] TIOFEN-4-IL-PIPERAZIN-1-IL) BUTOXI] -1H-QUINOLIN-2-ONA |
| KR20150016405A (en) | 2012-06-06 | 2015-02-11 | 오렉시젠 세러퓨틱스 인크. | Methods of treating overweight and obesity |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082864A (en) * | 1987-12-06 | 1992-01-21 | Akzo N.V. | Stabilized solutions of psychotropic agents |
| US5208261A (en) * | 1989-12-06 | 1993-05-04 | Akzo N.V. | Stabilized solutions of psychotropic agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL189199C (en) * | 1975-04-05 | 1993-02-01 | Akzo Nv | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS WITH ACTION ON THE CENTRAL NERVOUS SYSTEM BASED ON BENZ (ARYL) AZEPINE DERIVATIVES, THE PHARMACEUTICAL PREPARATIONS OBTAINED, AND METHOD FOR PREPARING THE PRODUCT TO BE USED. |
| AU8770282A (en) * | 1981-08-27 | 1983-03-03 | Shaun R. Coughlin | Composition for the treatment of atherosclerosis |
| US4940585A (en) * | 1989-02-17 | 1990-07-10 | Hapworth William E | Method for the treatment of nicotine withdrawal syndrome |
| US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| TW587938B (en) * | 1997-03-27 | 2004-05-21 | Akzo Nobel Nv | Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder |
| DE69811378T2 (en) * | 1997-10-03 | 2004-02-12 | Cary Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) | COMPOSITIONS FOR TREATING NICOTINE DEPENDENCY, CONTAINING MECAMYLAMINE AND BUPROPION |
-
1997
- 1997-06-13 IL IL12107697A patent/IL121076A/en not_active IP Right Cessation
- 1997-06-16 US US08/876,346 patent/US5977099A/en not_active Expired - Fee Related
- 1997-06-16 SG SG1997002068A patent/SG60073A1/en unknown
- 1997-06-17 DE DE69710390T patent/DE69710390T2/en not_active Expired - Fee Related
- 1997-06-17 ZA ZA9705335A patent/ZA975335B/en unknown
- 1997-06-17 PT PT97201853T patent/PT813873E/en unknown
- 1997-06-17 ES ES97201853T patent/ES2172744T3/en not_active Expired - Lifetime
- 1997-06-17 NZ NZ328113A patent/NZ328113A/en unknown
- 1997-06-17 AT AT97201853T patent/ATE213159T1/en not_active IP Right Cessation
- 1997-06-17 DK DK97201853T patent/DK0813873T3/en active
- 1997-06-17 CZ CZ19971870A patent/CZ290691B6/en not_active IP Right Cessation
- 1997-06-18 HU HU9701068A patent/HU225534B1/en not_active IP Right Cessation
- 1997-06-18 PL PL97320628A patent/PL188520B1/en not_active IP Right Cessation
- 1997-06-18 BR BR9703624A patent/BR9703624A/en not_active Application Discontinuation
- 1997-06-18 KR KR1019970025307A patent/KR100481254B1/en not_active IP Right Cessation
- 1997-06-18 CA CA002208199A patent/CA2208199C/en not_active Expired - Fee Related
- 1997-06-18 RU RU97110083/14A patent/RU2181287C2/en not_active IP Right Cessation
- 1997-06-18 NO NO19972816A patent/NO313177B1/en unknown
- 1997-06-19 AR ARP970102687A patent/AR007609A1/en active IP Right Grant
- 1997-06-19 TR TR97/00522A patent/TR199700522A2/en unknown
- 1997-06-19 ID IDP972117A patent/ID17051A/en unknown
- 1997-06-19 JP JP16257697A patent/JP4925074B2/en not_active Expired - Fee Related
- 1997-06-19 CN CN97115549A patent/CN1132581C/en not_active Expired - Fee Related
- 1997-06-19 AU AU26129/97A patent/AU727851B2/en not_active Ceased
-
1998
- 1998-06-16 HK HK98105337A patent/HK1006081A1/en not_active IP Right Cessation
-
2008
- 2008-12-12 JP JP2008317326A patent/JP2009137970A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082864A (en) * | 1987-12-06 | 1992-01-21 | Akzo N.V. | Stabilized solutions of psychotropic agents |
| US5208261A (en) * | 1989-12-06 | 1993-05-04 | Akzo N.V. | Stabilized solutions of psychotropic agents |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1132581C (en) | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitiors | |
| AU781827B2 (en) | Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation | |
| US6403121B1 (en) | Core formulation | |
| CA3229053A1 (en) | Method of maintaining remission of depressive symptoms | |
| JPH0393718A (en) | Medicine for therapy of premature ejacula- tion | |
| JP2010065060A (en) | Composite treatment for heart failure treatment | |
| KR102059027B1 (en) | Pharmaceutical Composition Comprising Inhibitor of HDAC6 for Preventing or Treating Itch | |
| TWI826380B (en) | Nk-1 antagonist compositions and methods for use in treating depression | |
| US6461639B2 (en) | Core formulation | |
| EP0813873B1 (en) | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
| SK2582004A3 (en) | Use of desoxypeganine for treating clinical depression | |
| KR20010099648A (en) | A New Composition | |
| TW592702B (en) | Pharmaceutical composition for treating diabetes | |
| JP2009537601A (en) | Mirtazapine for the treatment of neuropathic pain | |
| WO2000006139A2 (en) | Use of moclobemide and metabolites for treating and preventing substance abuse | |
| EP3996699A1 (en) | Combination of ibuprofen and tramadol for relieving pain | |
| CN1355696A (en) | Method to aid smoking cessation | |
| MXPA97004579A (en) | Pharmaceutical composition comprising mirtazapine and one or more selective seroton reabsorption inhibitors | |
| JP2005500344A (en) | Treatment of chronic pain with 3-aryloxy-3-phenylpropanamine | |
| ZA200300220B (en) | Compounds for the treatment of addictive disorders. | |
| JPH0366628A (en) | Agent for activating exercise of alimentary canal | |
| JPS6148482B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ORGANON NV Free format text: FORMER OWNER: AKZO NOVEL N.V. CORP. Effective date: 20070105 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20070105 Address after: Holland Patentee after: Organon NV Address before: Holland Arnhem Patentee before: Akzo Nobel N. V. |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20031231 |